Navigation Links
Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
Date:5/17/2011

ional product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the QNEXA End of Review meeting; our response to, and continued dialogue with, the FDA relating to matters raised in the FDA's CRL for QNEXA; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; the review and questions from the EMA and CHMP on the MAA; substantial competition; the impact on future sales based o
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Creekridge Capital, an independent vendor-focused finance ... so far in 2014 to their portfolio of ... from both the healthcare and technology industries. They ... multi-national companies. Each of these new vendors take ... including: standard leasing products, subscription solutions, a dedicated ...
(Date:7/23/2014)... -- When it comes to welcoming our new robot overlords, InformationWeek ... the red carpet. Healthcare is one of the ... into our human sphere. With healthcare concerns top of mind ... apply new technologies to help with old problems. That,s where ... expected to increase from $1.7 billion now to $3.7 billion ...
(Date:7/23/2014)... 2014  Researchers from the North American Menopause Society ... calcium levels too high, 1 putting women at ... Women close to menopause are commonly told to ... diseases such as osteoporosis, to which they are particularly ... how much calcium they typically get through their food ...
Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Women Taking Too Much Calcium Create Health Risk 2
... announces that a new market research report is ... Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and ... http://www.reportlinker.com/p0479828/Juvenile-Rheumatoid-Arthritis-JRA-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html Juvenile Rheumatoid Arthritis (JRA) ... 2017 Summary ...
... announces that a new market research report is ... Cancer Therapy Area Pipeline Report ... Therapy Area Pipeline Report contains detailed information on ... insight into the pipeline status of pancreatic cancer ...
Cached Medicine Technology:Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Pancreatic Cancer Therapy Area Pipeline Report 2Reportlinker Adds Pancreatic Cancer Therapy Area Pipeline Report 3
(Date:7/23/2014)... and young adults living near Sellafield or Dounreay since ... developing cancer according to research published in the ... from the Childhood Cancer Research Group at the University ... between 1963 and 2006 among those who were under ... No difference was found in cancer incidence from 1991-2006 ...
(Date:7/23/2014)... 2014 A new study has uncovered ... ( http://www.injurybeacon.com/power-morcellator/ ) during minimally invasive hysterectomies can ... woman’s body, Bernstein Liebhard LLP reports. The research, which ... the American Medical Association, looked at 36,000 women who ... U.S. hospitals from 2006 to 2012. Ninety-nine of the ...
(Date:7/23/2014)... patients if a suspicious skin lesion is painful or ... likely to be cancerous, according to a new study ... of Dermatology at Temple University School of Medicine. , ... on July 23, 2014, found that nearly 36. 9 ... while 28.2 percent involve pain. Non-melanoma skin cancers ...
(Date:7/23/2014)... -- Painful or itchy skin lesions could be a ... sometimes have multiple lesions that are suspicious looking, and ... concerns for non-melanoma skin cancers," study author Dr. Gil ... Medicine, said in a Temple University Health System news ... 268 patients who were confirmed to have skin cancer ...
(Date:7/23/2014)... Rich Dad® Education, a leader in financial education, is ... to support Habit for Humanity of Lee and Hendry Counties. ... be donated to Habitat for Humanity. Additionally, all the items ... Habitat for Humanity ReStore thrift store located at 31 Willis ... the highlights of the yard sale was a visit from ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2
... its smoking ban to entertainment outlets including pubs, nightclubs ... cut tobacco-related diseases. ,The ban will ... city-state which already has some of the toughest anti-smoking ... restrict smoking in entertainment outlets is a natural extension ...
... opportunity for superstition and marketing to come together: starry-eyed couples ... Earth concerts as well as the proclamation of the world's ... 7 has a magic sacred side and the reputation of ... bring an extra dose of good fortune. ,"Number ...
... Brahmachari and Dr. MRS Rao will be jointly awarded the ... 2005 for their outstanding contribution in the field of bio-medical ... one lakh. ,Besides, the Indian Council of Medical ... country to be honoured for their outstanding contributions in research ...
... prospective study suggests that ovarian germ cell tumour ... may retain their menstrual function and reproductive ... the Journal of Clinical Oncology, also found that ... more likely than their healthy counterparts to be ...
... a cure for smelly and pongy feet - special socks made ... eco-friendly sock to go on general sale, and experts have forecasted ... to take place in the world of clothing. ... of the silky material, which is softer, more durable and absorbent ...
... a slew of studies have highlighted the adverse effects of ... hours of gaming can actually be good for children. ... competing against each other give children a chance to learn ... and other races. ,The study by researchers from ...
Cached Medicine News:Health News:Singapore Extends Smoking Ban to Pubs, Nightclubs 2Health News:A Lucky Number? 7/7/07 2Health News:A Lucky Number? 7/7/07 3Health News:Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability 2Health News:Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability 3Health News:Exposure to Computer Games can Be 'good' for Kids, Says New Study 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: